DELIVERY OF DIAGNOSTIC AND THERAPEUTIC MABS TO CNS

Medicine & Life Sciences

1. Brain Neoplasms 100%
2. Blood-Brain Barrier 47%
3. Neoplasms 43%
4. BR96 monoclonal antibody 39%
5. Drug Therapy 34%
6. monocrystalline iron oxide nanoparticle 24%
7. Therapeutics 21%
8. Radioimmunotherapy 20%
9. Nude Rats 18%
10. Permeability 17%
11. Immunoconjugates 16%
12. Acetylcysteine 16%
13. Rituximab 16%
14. Sulfhydryl Compounds 16%
15. Pharmaceutical Preparations 15%
16. Monoclonal Antibodies 14%
17. Immunotherapy 13%
18. Heterografts 12%
19. DNA alkyltransferase 12%
20. sodium thiosulfate 11%
21. Lymphoma 11%
22. Yttrium-90 11%
23. National Institute of Neurological Disorders and Stroke (U.S.) 11%
24. Bone Marrow 11%
25. Beta Particles 10%
26. Buthionine Sulfoximine 10%
27. Central Nervous System 10%
28. Lewis Blood Group Antigens 9%
29. Magnetic Resonance Imaging 9%
30. Clinical Trials 9%
31. Exotoxins 8%
32. Immunoglobulin Fragments 8%
33. ferric oxide 7%
34. Pseudomonas 7%
35. Small Cell Lung Carcinoma 7%
36. Drug-Related Side Effects and Adverse Reactions 6%
37. Brain 6%
38. Glutathione 6%
39. Drug Combinations 6%
40. Growth 6%
41. Contrast Media 5%